GALECTIN THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 173.91K shares, a 38.02% decline year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 173.33K shares, a 162.63% increase year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 529.16K shares, a 16.62% increase year-over-year.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 214.40K shares.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.09M shares, a 116.59% increase from fiscal 2024.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 503.33K shares.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- GALECTIN THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 173.91K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 1.09M shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 173.33K shares 10-Q · filed 2026-05-15 | 1.20M shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 529.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 1.09M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 214.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 1.01M shares derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-06-30 | 280.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 800.36K shares derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-03-31 | 66.00K shares 10-Q · filed 2025-05-15 | 527.25K shares derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | 453.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 503.33K shares 10-K · filed 2026-03-31 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 49.58K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | 7.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 49.58K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | 42.08K shares 10-Q · filed 2024-05-15 | 42.08K shares derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 0.00 shares 10-K · filed 2025-03-31 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | 0.00 shares derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 0.00 shares derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 0.00 shares 10-K · filed 2024-03-29 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -247.72K shares derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -103.56K shares derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-16 | 78.94K shares derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-12-31 | -247.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 148.94K shares 10-K · filed 2023-03-30 |
| 2021-09-30 | 144.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 396.66K shares derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-06-30 | 182.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | 252.50K shares derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | 70.00K shares 10-Q · filed 2021-05-17 | 70.00K shares derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 84.62K shares 10-K · filed 2022-03-31 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | 93.07K shares derived: sum of 4 quarters · filed 2021-03-31 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 93.07K shares derived: sum of 4 quarters · filed 2021-03-31 |
| 2020-03-31 | 84.62K shares 10-Q · filed 2020-05-11 | 101.78K shares derived: sum of 4 quarters · filed 2021-03-31 |
| 2019-12-31 | 8.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | 150.99K shares 10-K · filed 2021-03-31 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 48.01K shares derived: sum of 4 quarters · filed 2020-03-16 |
| 2019-06-30 | 8.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | 411.85K shares derived: sum of 4 quarters · filed 2020-03-16 |
| 2019-03-31 | 133.84K shares 10-Q · filed 2019-05-10 | 2.23M shares derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-12-31 | -94.54K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 2.10M shares 10-K · filed 2020-03-16 |
| 2018-09-30 | 363.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 2.19M shares derived: sum of 4 quarters · filed 2019-03-06 |
| 2018-06-30 | 1.83M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | 1.83M shares derived: sum of 4 quarters · filed 2019-03-06 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2018-05-11 | 0.00 shares derived: sum of 4 quarters · filed 2019-03-06 |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | 0.00 shares 10-K · filed 2019-03-06 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 0.00 shares derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 0.00 shares derived: sum of 4 quarters · filed 2018-03-29 |
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2018-03-29 |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | 0.00 shares 10-K · filed 2018-03-29 |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08 | 0.00 shares derived: sum of 4 quarters · filed 2017-03-28 |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | 0.00 shares derived: sum of 4 quarters · filed 2017-03-28 |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-10 | 0.00 shares derived: sum of 4 quarters · filed 2017-03-28 |
| 2015-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-28 | 95.57K shares 10-K · filed 2017-03-28 |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -8.71K shares derived: sum of 4 quarters · filed 2016-03-15 |
| 2015-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -66.00 shares derived: sum of 4 quarters · filed 2016-03-15 |
| 2015-03-31 | 95.57K shares 10-Q · filed 2015-05-11 | 53.27K shares derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-12-31 | -104.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | 246.44K shares 10-K · filed 2016-03-15 |
| 2014-09-30 | 8.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | 407.39K shares derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | 53.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 452.50K shares derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | 288.75K shares 10-Q · filed 2014-05-13 | 462.00K shares derived: sum of 4 quarters · filed 2016-03-15 |
| 2013-12-31 | 56.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | 213.01K shares 10-K · filed 2016-03-15 |
| 2013-09-30 | 53.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | 156.35K shares derived: sum of 4 quarters · filed 2015-03-18 |
| 2013-06-30 | 62.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | 102.59K shares derived: sum of 4 quarters · filed 2015-03-18 |
| 2013-03-31 | 39.76K shares 10-Q · filed 2013-05-10 | |
| 2012-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-18 | 51.83K shares 10-K · filed 2015-03-18 |
| 2012-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | |
| 2011-12-31 | 216.44K shares 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |